In today’s briefing:
- Gilead Sciences: A Tale Of Continued Growth in Oncology and HIV Sectors! – Major Drivers
- SAM Holdings – Building a One-Stop Cancer Treatment Centre – Debuts on SGX
- InMed Pharmaceuticals, Inc. – Revenues Flowing, Drug Development Pipeline Advancing
Gilead Sciences: A Tale Of Continued Growth in Oncology and HIV Sectors! – Major Drivers
- Gilead Sciences exhibited a sturdy performance in 2023, driven by a 7% growth in product sales, excluding revenue from Veklury.
- Significant sales growth was witnessed in HIV and oncology, with HIV sales growing by about $1 billion and oncology sales growing 37%, largely offsetting the decline in Veklury revenue.
- The robust growth in product sales paves the way for Gilead’s outlook for 2024 and its commitment to addressing high-demand clinical portfolios.
SAM Holdings – Building a One-Stop Cancer Treatment Centre – Debuts on SGX
- The operator of two medical clinics in Singapore – Singapore Institute of Advanced Medicine (SAM Holdings) is among the first in the nation to install the ProBeam Proton Therapy Solution, an advanced technology used to treat cancer.
- SAM Holdings made its debut on the SGX Catalist today.
- The Varian ProBeam Compact is capable of emitting pencil beam proton therapy to deliver precision proton beam therapy to treat cancer patients, placing the company at the forefront of medical technology in the field of radiation therapy for cancer treatment in Singapore.
InMed Pharmaceuticals, Inc. – Revenues Flowing, Drug Development Pipeline Advancing
- BayMedica reports another strong quarter. The commercial business operating arm of InMed reported revenue of $1.24 million for the quarter ended December 30, 2023, representing a 164% Y/Y increase and 38% Q/Q growth.
- Revenue for the quarter exceeded our estimate of $1.13 million. BayMedica has now recorded quarterly revenue of more than $1 million in three of the last four quarters.
- For the first six months of the current fiscal year ending June 30, 2024, revenue climbed 171% to $2.1 million from $0.8 million in 1HFY23.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
